Description

Simple

A medication used to treat a wide variety of cancers and certain skin conditions caused by viruses.

Clinical

A vinca alkaloid used to treat breast cancer, testicular cancer, neuroblastoma, Hodgkin's and non-Hodgkins lymphoma, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Overview

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Pharmacology

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Pharmacodynamic

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extract... Read more

Mechanism of action

The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.

Absorption

Information currently not available.

Protein binding

98-99%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Triphasic: 35 min, 53 min, and 19 hours

Route of elimination

The major route of excretion may be through the biliary system.

Toxicity

Oral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Bacterial Infections
      • Drugbank Id: DBCOND0027917
  • Regions: US
  • Patient Conditions:
      • Name: Significant granulocytopenia
      • Drugbank Id: DBCOND0107840

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vinblastine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be increased when combined with Vinblastine.
(S)-Warfarin
The metabolism of (S)-Warfarin can be increased when combined with Vinblastine.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Vinblastine is combined with 2-Methoxyethanol.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be increased when combined with Vinblastine.
4-Methoxyamphetamine
The metabolism of 4-Methoxyamphetamine can be decreased when combined with Vinblastine.
5-methoxy-N,N-dimethyltryptamine
The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Vinblastine.
6-Deoxyerythronolide B
The serum concentration of Vinblastine can be increased when it is combined with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Vinblastine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be increased when combined with Vinblastine.
Abatacept
The risk or severity of adverse effects can be increased when Vinblastine is combined with Abatacept.
Abciximab
The risk or severity of bleeding can be increased when Abciximab is combined with Vinblastine.
Abetimus
The risk or severity of adverse effects can be increased when Vinblastine is combined with Abetimus.
Acebutolol
The metabolism of Acebutolol can be decreased when combined with Vinblastine.
Acenocoumarol
The metabolism of Acenocoumarol can be increased when combined with Vinblastine.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Vinblastine.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Vinblastine.
Acteoside
The risk or severity of adverse effects can be increased when Vinblastine is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Vinblastine.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Vinblastine.
Afatinib
The serum concentration of Vinblastine can be increased when it is combined with Afatinib.
1 References
  1. 1 . Starling D: Two ultrastructurally distinct tubulin paracrystals induced in sea-urchin eggs by vinblastine sulphate. J Cell Sci. 1976 Jan;20(1):79-89.PubMed: 942954